Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.

Volume: 41, Pages: 105 - 119
Published: Jan 17, 2019
Abstract
null null Background null Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due to acquired resistance, such as secondary mutations in ALK including I1171N and G1202R. Although ceritinib or lorlatinib was shown to be effective to these resistant mutants, further resistance often emerges due to ALK-compound mutations in relapse patients following the use of...
Paper Details
Title
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Published Date
Jan 17, 2019
Volume
41
Pages
105 - 119
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.